Gram-positive bacteria specific binding compounds

Patent metadata

Field	Value
Publication number	US-9399673-B2
Application number	US-201313786206-A
Country	US
Kind code	B2
Filing date	Mar 5, 2013
Priority date	Jul 15, 2009
Publication date	Jul 26, 2016
Grant date	Jul 26, 2016

Abstract

The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.

First claim

We claim:

1. An antibody or antigen-binding part thereof that binds to a serine-aspartate (SD) repeat-dependent epitope of an SD repeat (sdr) protein, wherein the SD repeat-dependent epitope comprises the amino acid sequence of SEQ ID NO: 34, and wherein the antibody or antigen-binding part thereof is coupled to a cytotoxic agent to form an antibody-drug conjugate.

2. The antibody or antigen-binding part thereof of claim 1 , wherein the sdr protein is located on the surface of a bacterium.

3. The antibody or antigen-binding part thereof of claim 1 , wherein the sdr protein is anchored to the peptidoglycan cell wall of a gram-positive bacterium.

4. The antibody or antigen-binding part thereof of claim 3 , wherein the gram positive bacterium is a Staphylococcus species.

5. The antibody or antigen-binding part thereof of claim 4 , wherein the bacterium is S. aureus.

6. The antibody or antigen-binding part thereof of claim 5 , wherein the sdr protein is selected from the group consisting of ClfA (SdrA), ClfB (SdrB), SdrC, SdrD and SdrE.

7. The antibody or antigen-binding part thereof of claim 4 , wherein the bacterium is S. epidermidis.

8. The antibody or antigen-binding part thereof of claim 7 , wherein the sdr protein is selected from the group consisting of SdrF, SdrG and SdrH.

9. The antibody or antigen-binding part thereof of claim 4 , wherein the bacterium is S. saprophyticus.

10. The antibody or antigen-binding part thereof of claim 9 , wherein the sdr protein is SdrI.

11. The antibody or antigen-binding part thereof of claim 4 , wherein the bacterium is S. capitis.

12. The antibody or antigen-binding part thereof of claim 11 , wherein the sdr protein is SdrX.

13. The antibody or antigen-binding part thereof of claim 4 , wherein the bacterium is S. caprae.

14. The antibody or antigen-binding part thereof of claim 13 , wherein the sdr protein is selected from the group consisting of SdrY and SdrZ.

15. The antibody or antigen-binding part thereof of claim 1 , wherein the cytotoxic agent is an antibiotic.

16. The antibody or antigen-binding part thereof of claim 1 , wherein the antibody or antigen-binding part thereof binds to cell wall lysates from S. aureus and/or S. epidermis.

17. The antibody or antigen-binding part thereof of claim 1 , wherein the antigen-binding part is a single domain antibody, a single chain antibody, a nanobody, an unibody, a single chain variable fragment (scFv), a Fab fragment or a F(ab′) 2 fragment.

Assignees

• Genentech Inc
• Aimm Therapeutics Bv

Inventors

• Beaumont Tim
• Kwakkenbos Mark Jeroen
• Brown Eric J
• Morisaki John Hiroshi
• Hazenbos Wouter L W
• Mariathasan Sanjeev
• Kajihara Kimberly
• Xia Yi

Classifications

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P37/04

  Immunostimulants · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C07K2317/52

  Constant or Fc region; Isotype · CPC title